Aquestive Therapeutics, Inc. (AQST) vs Nuvectis Pharma, Inc. (NVCT)

A side-by-side comparison of Aquestive Therapeutics, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AQST

Aquestive Therapeutics, Inc.

$578M

$4.61HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

NVCT

Nuvectis Pharma, Inc.

$532M

$20.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AQST vs NVCT

growth of $100 · dividends reinvested · last 5y

AQST +72.5% (+11.5%/yr)NVCT +558.2% (+45.8%/yr)NVCT compounded faster over this window

AQST NVCT

AQST vs NVCT: by the numbers

•AQST is the larger company ($578M vs $532M market cap).
•Both run net losses; NVCT's is the smaller (0.00% vs -144.63% net margin).

Metrics side by side

Valuation

Metric	AQST	NVCT
P/S ratio	10.69	N/A
P/B ratio	N/A	58.53

Profitability

Metric	AQST	NVCT
Gross margin	67.04%	0.00%
Operating margin	-156.36%	0.00%
Net margin	-144.63%	0.00%
ROE	N/A	-306.61%
ROIC	-45.62%	-317.86%

Growth (annualized)

Metric	AQST	NVCT
Revenue CAGR (5Y)	-0.58%	N/A
Total return CAGR (5Y)	2.24%	N/A

Go deeper

Full AQST analysis Full NVCT analysis Interactive comparison tool

Dig into the metrics

Aquestive Therapeutics ROE Nuvectis Pharma ROE Aquestive Therapeutics operating margin Nuvectis Pharma operating margin Aquestive Therapeutics revenue growth Nuvectis Pharma revenue growth Aquestive Therapeutics free cash flow Nuvectis Pharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.